Genmab A/S announced its plans to present new research from its late-stage oncology portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S) in patients with recurrent/advanced endometrial cancer.
Additionally, results from an analysis of the Phase 1/2 EPCORE NHL-1 study of epcoritamab will be presented. This includes long-term follow-up data in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who remain in complete response at two years.
Genmab expressed particular encouragement regarding Rina-S as a potential treatment option for endometrial cancer, noting it is one of the few cancers with rising mortality rates and limited treatment options. The company, in collaboration with AbbVie, continues to evaluate epcoritamab as a potential core therapy across B-cell malignancies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.